# Early Immunotherapy with Intravenous Immunoglobulin, Cyclophosphamide and Methylprednisolone in Patients with Anti-Hu-associated Paraneoplastic Sensory Neuronopathy

> **NCT06373211** · PHASE2 · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 21 (estimated)

## Conditions studied

- Paraneoplastic Sensory Neuronopathy

## Interventions

- **DRUG:** Immunoglobulins IV (CLAYRIG)
- **DRUG:** Cyclophosphamide IV
- **DRUG:** Methylprednisolone IV

## Key facts

- **NCT ID:** NCT06373211
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-10
- **Primary completion:** 2028-06
- **Final completion:** 2028-06
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2025-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06373211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06373211, "Early Immunotherapy with Intravenous Immunoglobulin, Cyclophosphamide and Methylprednisolone in Patients with Anti-Hu-associated Paraneoplastic Sensory Neuronopathy". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT06373211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*